Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02064764 · ClinicalTrials.gov registry record · NA

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

A NA study, sponsored by Medtronic Vascular.

Completed
Registry status
NA
Development phase
102
Enrollment target

NCT02064764 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 102 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02064764, a NA study, has completed, sponsored by Medtronic Vascular.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target

Study Summary

The purpose of this clinical study is to evaluate the feasibility of performing both renal nerve denervation and pulmonary vein isolation on the same patient with the intent of characterizing both safety and effectiveness in a paroxysmal and persistent atrial fibrillation population with hypertension. To assess safety, the study will measure the occurrence of a composite safety endpoint and, to assess effectiveness, the study will measure freedom of chronic treatment failure through a minimum of six months of follow-up.

Interventions

  • DEVICE Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter
  • DEVICE Arctic Front Advance™ Cardiac Cryoablation System

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2015-02
Est. Completion 2021-04-19
Phase NA

Sponsor

Medtronic Vascular

26 total trials

What the Registry Record Tells You About NCT02064764

The ClinicalTrials.gov registry entry for NCT02064764 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter is the first listed.

NCT02064764 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02064764 about?

NCT02064764 is a clinical study titled "Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation". The purpose of this clinical study is to evaluate the feasibility of performing both renal nerve denervation and pulmonary vein isolation on the same patient with the intent of characterizing both safety and effectiveness in a paroxysmal and persistent atrial fibrillation population with hypertensio...

What is the current status of trial NCT02064764?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2015-02. Estimated completion is 2021-04-19.

What interventions are being tested in trial NCT02064764?

The interventions under investigation include: Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter (DEVICE), Arctic Front Advance™ Cardiac Cryoablation System (DEVICE).

Who is sponsoring clinical trial NCT02064764?

This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.